Skip to main content
Top
Published in: Acta Diabetologica 12/2020

Open Access 01-12-2020 | Prediabetes | Original Article

Toward targeted prevention: risk factors for prediabetes defined by impaired fasting glucose, impaired glucose tolerance and increased HbA1c in the population-based KORA study from Germany

Authors: Gregory G. Greiner, Karl M. F. Emmert-Fees, Jana Becker, Wolfgang Rathmann, Barbara Thorand, Annette Peters, Anne S. Quante, Lars Schwettmann, Michael Laxy

Published in: Acta Diabetologica | Issue 12/2020

Login to get access

Abstract

Aims

To identify socioeconomic, behavioral and clinical factors that are associated with prediabetes according to different prediabetes definition criteria.

Methods

Analyses use pooled data of the population-based Cooperative Health Research in the Region of Augsburg (KORA) studies (n = 5312 observations aged ≥ 38 years without diabetes). Prediabetes was defined through either impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or elevated HbA1c according to thresholds of the American Diabetes Association. Explanatory variables were regressed on prediabetes using generalized estimating equations.

Results

Mean age was 58.4 years; 50% had prediabetes (33% had IFG, 16% IGT, and 26% elevated HbA1c, 10% fulfilled all three criteria). Age, obesity, hypertension, low education, unemployment, statutory health insurance, urban residence and physical inactivity were associated with prediabetes. Male sex was a stronger risk factor for IFG (OR = 2.5; 95%–CI: 2.2–2.9) than for IGT or elevated HbA1c, and being unemployed was a stronger risk factor for IGT (OR = 3.2 95%–CI: 2.6–4.0) than for IFG or elevated HbA1c.

Conclusions

The overlap of people with IFG, IGT and elevated HbA1c is small, and some factors are associated with only one criterion. Knowledge on sociodemographic and socioeconomic risk factors can be used to effectively target interventions to people at high risk for type 2 diabetes.
Appendix
Available only for authorised users
Literature
3.
go back to reference Hex N, Bartlett C, Wright D, Taylor M, Varley D (2012) Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 29:855–862CrossRefPubMed Hex N, Bartlett C, Wright D, Taylor M, Varley D (2012) Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 29:855–862CrossRefPubMed
4.
go back to reference Seuring T, Archangelidi O, Suhrcke M (2015) The economic costs of type 2 diabetes: a global systematic review. Pharmacoecon Open 33:811–831CrossRef Seuring T, Archangelidi O, Suhrcke M (2015) The economic costs of type 2 diabetes: a global systematic review. Pharmacoecon Open 33:811–831CrossRef
5.
go back to reference World Health Organization (2016) Global report on diabetes. World Health Organization, Geneva World Health Organization (2016) Global report on diabetes. World Health Organization, Geneva
6.
go back to reference Ogurtsova K, da Rocha Fernandes JD, Huang Y et al (2017) IDF Diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50CrossRefPubMed Ogurtsova K, da Rocha Fernandes JD, Huang Y et al (2017) IDF Diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50CrossRefPubMed
7.
8.
go back to reference Ananthapavan J, Sacks G, Moodie M, Carter R (2014) Economics of obesity—learning from the past to contribute to a better future. Int J Environ Res Public Health 11:4007–4025CrossRefPubMedPubMedCentral Ananthapavan J, Sacks G, Moodie M, Carter R (2014) Economics of obesity—learning from the past to contribute to a better future. Int J Environ Res Public Health 11:4007–4025CrossRefPubMedPubMedCentral
9.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
10.
go back to reference Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol 3(11):866–875CrossRefPubMedCentral Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol 3(11):866–875CrossRefPubMedCentral
11.
go back to reference Lindström J, Louheranta A, Mannelin M et al (2003) The Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26:3230–3236CrossRefPubMed Lindström J, Louheranta A, Mannelin M et al (2003) The Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26:3230–3236CrossRefPubMed
12.
go back to reference Gong Q, Zhang P, Wang J et al (2019) Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing diabetes prevention outcome study. Lancet Diabetes Endocrinol 7:452–461CrossRefPubMedPubMedCentral Gong Q, Zhang P, Wang J et al (2019) Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing diabetes prevention outcome study. Lancet Diabetes Endocrinol 7:452–461CrossRefPubMedPubMedCentral
13.
go back to reference Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X (2010) Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 33:1872–1894CrossRefPubMedPubMedCentral Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X (2010) Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 33:1872–1894CrossRefPubMedPubMedCentral
14.
go back to reference Diabetes Prevention Program Research Group (2012) The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35(4):723–730 [published correction appears in Diabetes Care. 2013 Dec;36(12):4173-5]CrossRef Diabetes Prevention Program Research Group (2012) The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35(4):723–730 [published correction appears in Diabetes Care. 2013 Dec;36(12):4173-5]CrossRef
15.
go back to reference Neumann A, Lindholm L, Norberg M, Schoffer O, Klug SJ, Norström F (2017) The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program. Eur J Health Econ 18:905–919CrossRefPubMed Neumann A, Lindholm L, Norberg M, Schoffer O, Klug SJ, Norström F (2017) The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program. Eur J Health Econ 18:905–919CrossRefPubMed
16.
go back to reference Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z (2007) Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 30:2548–2552CrossRefPubMed Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z (2007) Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 30:2548–2552CrossRefPubMed
17.
go back to reference Zhuo X, Zhang P, Selvin E et al (2012) Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective. Am J Prev Med 42:374–381CrossRefPubMed Zhuo X, Zhang P, Selvin E et al (2012) Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective. Am J Prev Med 42:374–381CrossRefPubMed
18.
go back to reference American Diabetes Association 2 (2018) Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41:S13–S27CrossRef American Diabetes Association 2 (2018) Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41:S13–S27CrossRef
19.
go back to reference Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T (2017) Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 356:i6538CrossRefPubMed Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T (2017) Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 356:i6538CrossRefPubMed
20.
go back to reference Holle R, Happich M, Löwel H, Wichmann HE (2005) KORA—a research platform for population based health research. Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 67(Suppl 1):S19–S25CrossRef Holle R, Happich M, Löwel H, Wichmann HE (2005) KORA—a research platform for population based health research. Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 67(Suppl 1):S19–S25CrossRef
21.
go back to reference Laxy M, Knoll G, Schunk M, Meisinger C, Huth C, Holle R (2016) Quality of diabetes care in Germany improved from 2000 to 2007 to 2014, but improvements diminished since 2007. Evidence from the population-based KORA studies. PLoS One 11:e0164704CrossRefPubMedPubMedCentral Laxy M, Knoll G, Schunk M, Meisinger C, Huth C, Holle R (2016) Quality of diabetes care in Germany improved from 2000 to 2007 to 2014, but improvements diminished since 2007. Evidence from the population-based KORA studies. PLoS One 11:e0164704CrossRefPubMedPubMedCentral
22.
go back to reference American Diabetes Association 2 (2015) Classification and diagnosis of diabetes. Diabetes Care 38(Suppl):S8–S16CrossRef American Diabetes Association 2 (2015) Classification and diagnosis of diabetes. Diabetes Care 38(Suppl):S8–S16CrossRef
23.
go back to reference World Health Organization and International Diabetes Federation (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. World Health Organization, Geneva World Health Organization and International Diabetes Federation (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. World Health Organization, Geneva
24.
go back to reference Bellou V, Belbasis L, Tzoulaki I, Evangelou E (2018) Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One 13:e0194127CrossRefPubMedPubMedCentral Bellou V, Belbasis L, Tzoulaki I, Evangelou E (2018) Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One 13:e0194127CrossRefPubMedPubMedCentral
25.
go back to reference World Health Organization (2011) Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. World Health Organization, Geneva World Health Organization (2011) Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. World Health Organization, Geneva
27.
go back to reference Saukkonen T, Cederberg H, Jokelainen J et al (2011) Limited overlap between intermediate hyperglycemia as defined by A1C 5.7–6.4%, impaired fasting glucose, and impaired glucose tolerance. Diabetes Care 34:2314–2316CrossRefPubMedPubMedCentral Saukkonen T, Cederberg H, Jokelainen J et al (2011) Limited overlap between intermediate hyperglycemia as defined by A1C 5.7–6.4%, impaired fasting glucose, and impaired glucose tolerance. Diabetes Care 34:2314–2316CrossRefPubMedPubMedCentral
28.
go back to reference Díaz-Redondo A, Giráldez-García C, Carrillo L et al (2015) Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). BMC Fam Pract 16:5CrossRefPubMedPubMedCentral Díaz-Redondo A, Giráldez-García C, Carrillo L et al (2015) Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). BMC Fam Pract 16:5CrossRefPubMedPubMedCentral
29.
go back to reference Schipf S, Werner A, Tamayo T et al (2012) Regional differences in the prevalence of known type 2 diabetes mellitus in 45–74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabet Med 29:e88–95CrossRefPubMed Schipf S, Werner A, Tamayo T et al (2012) Regional differences in the prevalence of known type 2 diabetes mellitus in 45–74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabet Med 29:e88–95CrossRefPubMed
30.
go back to reference Maier W, Holle R, Hunger M et al (2013) The impact of regional deprivation and individual socio-economic status on the prevalence of type 2 diabetes in Germany. A pooled analysis of five population-based studies. Diabet Med 30:e78–86CrossRefPubMed Maier W, Holle R, Hunger M et al (2013) The impact of regional deprivation and individual socio-economic status on the prevalence of type 2 diabetes in Germany. A pooled analysis of five population-based studies. Diabet Med 30:e78–86CrossRefPubMed
31.
go back to reference Bird Y, Lemstra M, Rogers M, Moraros J (2015) The relationship between socioeconomic status/income and prevalence of diabetes and associated conditions: a cross-sectional population-based study in Saskatchewan, Canada. Int J Equity Health 14:93CrossRefPubMedPubMedCentral Bird Y, Lemstra M, Rogers M, Moraros J (2015) The relationship between socioeconomic status/income and prevalence of diabetes and associated conditions: a cross-sectional population-based study in Saskatchewan, Canada. Int J Equity Health 14:93CrossRefPubMedPubMedCentral
32.
go back to reference Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W (2000) Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health 54:173–177CrossRefPubMedPubMedCentral Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W (2000) Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health 54:173–177CrossRefPubMedPubMedCentral
33.
go back to reference Morris DH, Khunti K, Achana F et al (2013) Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 56:1489–9334CrossRefPubMed Morris DH, Khunti K, Achana F et al (2013) Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 56:1489–9334CrossRefPubMed
34.
go back to reference Albright A (2012) The national diabetes prevention program: from research to reality. Diabetes Care Educ Newsl 33:4–7PubMedPubMedCentral Albright A (2012) The national diabetes prevention program: from research to reality. Diabetes Care Educ Newsl 33:4–7PubMedPubMedCentral
35.
go back to reference Centers for Disease Control and Prevention (2017) National diabetes statistics report, 2017. US Department of Health and Human Services, Atlanta, p 20 Centers for Disease Control and Prevention (2017) National diabetes statistics report, 2017. US Department of Health and Human Services, Atlanta, p 20
36.
go back to reference Ali MK, McKeever Bullard K, Imperatore G et al (2019) Reach and use of diabetes prevention services in the United States, 2016–2017. JAMA Netw Open 2:e193160CrossRefPubMedPubMedCentral Ali MK, McKeever Bullard K, Imperatore G et al (2019) Reach and use of diabetes prevention services in the United States, 2016–2017. JAMA Netw Open 2:e193160CrossRefPubMedPubMedCentral
37.
go back to reference Hoerger TJ, Hicks KA, Sorensen SW et al (2007) Cost-effectiveness of screening for pre-diabetes among overweight and obese US adults. Diabetes Care 30:2874–2879CrossRefPubMed Hoerger TJ, Hicks KA, Sorensen SW et al (2007) Cost-effectiveness of screening for pre-diabetes among overweight and obese US adults. Diabetes Care 30:2874–2879CrossRefPubMed
38.
go back to reference Lundgren RE, McMakin AH (eds) (2013) Risk communication: a handbook for communicating environmental, safety, and health risks, 5th edn. IEEE Press, Piscataway, pp 359–368 Lundgren RE, McMakin AH (eds) (2013) Risk communication: a handbook for communicating environmental, safety, and health risks, 5th edn. IEEE Press, Piscataway, pp 359–368
Metadata
Title
Toward targeted prevention: risk factors for prediabetes defined by impaired fasting glucose, impaired glucose tolerance and increased HbA1c in the population-based KORA study from Germany
Authors
Gregory G. Greiner
Karl M. F. Emmert-Fees
Jana Becker
Wolfgang Rathmann
Barbara Thorand
Annette Peters
Anne S. Quante
Lars Schwettmann
Michael Laxy
Publication date
01-12-2020
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 12/2020
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-020-01573-x

Other articles of this Issue 12/2020

Acta Diabetologica 12/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.